It’s time to rethink peer review policies—and consider an “Earth Shot Program”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

Login